STAT3 as a promising chemoresistance biomarker associated with the CD44+/high/CD24‐/low/ALDH+ BCSCs‐like subset of the triple‐negative breast cancer (TNBC) cell line

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Experimental Cell Research

• Publication date

  2018-02-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.yexcr.2018.01.018PMID 29352988
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• New 3‐alkylpyridine marine alkaloid analogues as promising antitumor agents against the CD44+/high/CD24−/low subset of triple‐negative breast cancer cell line

  2017cited by this paper
• The JAK/STAT3 axis: A comprehensive drug target for solid malignancies.

  2017cited by this paper
• Cancer statistics, 2017

  2017cited by this paper
• PKCδ Inhibition Impairs Mammary Cancer Proliferative Capacity But Selects Cancer Stem Cells, Involving Autophagy

  2016cited by this paper
• Nanoparticle-facilitated autophagy inhibition promotes the efficacy of chemotherapeutics against breast cancer stem cells.

  2016cited by this paper
• The cancer stem-cell signaling network and resistance to therapy.

  2016cited by this paper
• Kazinol-E is a specific inhibitor of ERK that suppresses the enrichment of a breast cancer stem-like cell population.

  2016cited by this paper
• Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy

  2016cited by this paper
• Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism.

  2016cited by this paper
• Cell Polarity Proteins in Breast Cancer Progression

  2016cited by this paper
• Genomic regulation of invasion by STAT3 in triple negative breast cancer

  2016cited by this paper
• AKT-ions with a TWIST between EMT and MET

  2016cited by this paper
• Cancer stem cells and chemoresistance: The smartest survives the raid.

  2016cited by this paper
• Persistent activation of STAT3 by PIM2-driven positive feedback loop for epithelial-mesenchymal transition in breast cancer

  2015cited by this paper
• Cytoplasmic p27 promotes epithelial–mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation

  2015cited by this paper
• EGFR tyrosine kinase inhibitors promote pro-caspase-8 dimerization that sensitizes cancer cells to DNA-damaging therapy

  2015cited by this paper
• Multiple regulation pathways and pivotal biological functions of STAT3 in cancer

  2015cited by this paper
• Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo

  2015cited by this paper
• Salinomycin Promotes Anoikis and Decreases the CD44+/CD24- Stem-Like Population via Inhibition of STAT3 Activation in MDA-MB-231 Cells

  2015cited by this paper
• Actin Cytoskeleton Regulation of Epithelial Mesenchymal Transition in Metastatic Cancer Cells

  2015cited by this paper
• Clinical implications of molecular heterogeneity in triple negative breast cancer.

  2015cited by this paper
• Over-Expressed Twist Associates with Markers of Epithelial Mesenchymal Transition and Predicts Poor Prognosis in Breast Cancers via ERK and Akt Activation

  2015cited by this paper
• Epithelial-mesenchymal plasticity of breast cancer stem cells: implications for metastasis and therapeutic resistance.

  2015cited by this paper
• An automated fitting procedure and software for dose-response curves with multiphasic features

  2015cited by this paper
• A Critical Dose of Doxorubicin Is Required to Alter the Gene Expression Profiles in MCF-7 Cells Acquiring Multidrug Resistance

  2015cited by this paper
• Novel strategies to enforce an epithelial phenotype in mesenchymal cells.

  2014cited by this paper
• Protein kinase C-delta inactivation inhibits the proliferation and survival of cancer stem cells in culture and in vivo

  2014cited by this paper
• STRING v10: protein–protein interaction networks, integrated over the tree of life

  2014cited by this paper
• An IL6-STAT3 loop mediates resistance to PI3K inhibitors by inducing epithelial-mesenchymal transition and cancer stem cell expansion in human breast cancer cells.

  2014cited by this paper
• Epithelial-to-mesenchymal transition: what is the impact on breast cancer stem cells and drug resistance.

  2014cited by this paper
• Companion Diagnostics and Cancer Biomarkers Coordinate Hyperactivation of Notch 1 and Ras / MAPK Pathways Correlates with Poor Patient Survival : Novel Therapeutic Strategy for Aggressive Breast Cancers

  2014cited by this paper
• The role of protein kinase-C theta in control of epithelial to mesenchymal transition and cancer stem cell formation

  2014cited by this paper
• RhoC Upregulation Is Correlated with Reduced E-cadherin in Human Breast Cancer Specimens After Chemotherapy and in Human Breast Cancer MCF-7 Cells

  2014cited by this paper
• Activation of STAT3 is involved in malignancy mediated by CXCL12-CXCR4 signaling in human breast cancer.

  2014cited by this paper
• MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial–mesenchymal transition

  2014cited by this paper
• The effect of a thieno[2,3- b ]pyridine PLC-γ inhibitor on the proliferation, morphology, migration and cell cycle of breast cancer cells

  2014cited by this paper
• Deguelin Action Involves c-Met and EGFR Signaling Pathways in Triple Negative Breast Cancer Cells

  2013cited by this paper
• Cancer stem‐like cell properties are regulated by EGFR/AKT/β–catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma

  2013cited by this paper
• The MEK-ERK Pathway Is Necessary for Serine Phosphorylation of Mitochondrial STAT3 and Ras-Mediated Transformation

  2013cited by this paper
• Evaluation of STAT3 Signaling in ALDH+ and ALDH+/CD44+/CD24− Subpopulations of Breast Cancer Cells

  2013cited by this paper
• Breast cancer stem cells: obstacles to therapy.

  2013cited by this paper
• Imatinib Reverses Doxorubicin Resistance by Affecting Activation of STAT3-Dependent NF-κB and HSP27/p38/AKT Pathways and by Inhibiting ABCB1

  2013cited by this paper
• Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells

  2013cited by this paper
• Protein Kinase C Zeta Regulates Human Pancreatic Cancer Cell Transformed Growth and Invasion through a STAT3-Dependent Mechanism

  2013cited by this paper
• Selective Small Molecule Stat3 Inhibitor Reduces Breast Cancer Tumor-Initiating Cells and Improves Recurrence Free Survival in a Human-Xenograft Model

  2012cited by this paper
• ERK1/2 Signaling Plays an Important Role in Topoisomerase II Poison-Induced G2/M Checkpoint Activation

  2012cited by this paper
• Role of epidermal growth factor receptor in breast cancer

  2012cited by this paper
• XZH-5 Inhibits STAT3 Phosphorylation and Enhances the Cytotoxicity of Chemotherapeutic Drugs in Human Breast and Pancreatic Cancer Cells

  2012cited by this paper
• Loss of the Par3 polarity protein promotes breast tumorigenesis and metastasis.

  2012cited by this paper
• Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population.

  2012cited by this paper
• Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells

  2012cited by this paper
• The selective inhibition of nuclear PKCζ restores the effectiveness of chemotherapeutic agents in chemoresistant cells

  2012cited by this paper
• The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.

  2011cited by this paper
• Activation by Tyrosine Phosphorylation as a Prerequisite for Protein Kinase Cζ to Mediate Epidermal Growth Factor Receptor Signaling to ERK

  2010cited by this paper
• Jnk signaling pathway-mediated regulation of Stat3 activation is linked to the development of doxorubicin resistance in cancer cell lines.

  2010cited by this paper
• Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

  2010cited by this paper
• Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

  2009cited by this paper
• Regulation of Mammary Stem/Progenitor Cells by PTEN/Akt/β-Catenin Signaling

  2009cited by this paper
• Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

  2008cited by this paper
• The epithelial-mesenchymal transition generates cells with properties of stem cells.

  2008cited by this paper
• Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists

  2008cited by this paper
• IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland.

  2007cited by this paper
• The STAT3 oncogene as a predictive marker of drug resistance.

  2007cited by this paper
• ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.

  2007cited by this paper
• Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties.

  2005cited by this paper
• RhoC-GTPase is a Novel Tissue Biomarker Associated with Biologically Aggressive Carcinomas of the Breast

  2005cited by this paper
• Prospective identification of tumorigenic breast cancer cells

  2003cited by this paper
• Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system.

  2003cited by this paper
• Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real-time PCR

  2002cited by this paper

• Identification of EEF1A1 as a therapeutic target in TNBC: Anticancer action of a novel Penicillide-derived inhibitor through ribosomal protein regulation.

  2026cites this paper
• Unraveling the role of 3-mercaptopyruvate sulfurtransferase-derived hydrogen sulfide in triple-negative breast cancer chemoresistance.

  2026cites this paper
• An update on cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer.

  2025cites this paper
• Targeting STAT3 pathway: A promising immunotherapeutic strategy for triple-negative breast cancer - Current status and future outlooks.

  2025cites this paper
• A novel CD44-targeting aptamer recognizes chemoresistant mesenchymal stem-like TNBC cells and inhibits tumor growth

  2025cites this paper
• Polyphenol-Mediated Antibody Functionalization of Titanium Peroxide Nanoparticles for Cancer Cell Targeting

  2025cites this paper
• Multiplexed sequential imaging in living cells with orthogonal fluorogenic RNA aptamer/dye pairs

  2024cites this paper
• RNA-Binding Proteins in Breast Cancer: Biological Implications and Therapeutic Opportunities.

  2024cites this paper
• Standard chemotherapy impacts on in vitro cellular heterogeneity in spheroids enriched with cancer stem cells (CSCs) derived from triple-negative breast cancer cell line.

  2024cites this paper
• The therapeutic effect of traditional Chinese medicine on breast cancer through modulation of the Wnt/β-catenin signaling pathway

  2024cites this paper
• Differentially expressed markers between chemoresistant and non-chemoresistant cells in TNB

  2023cites this paper
• STAT3 Signaling Axis and Tamoxifen in Breast Cancer: A Promising Target for Treatment Resistance.

  2023cites this paper
• Hypoxia-mediated activation of hypoxia-inducible factor-1α in triple-negative breast cancer: A review

  2023cites this paper
• Targeting Breast Cancer Stem Cells through Retinoids: A New Hope for Treatment.

  2023cites this paper
• Cancer stem cell markers interplay with chemoresistance in triple negative breast cancer: A therapeutic perspective.

  2022cites this paper
• Zinc complex of 3,5-di-tert-butyl salicylate inhibits viability, migration, and invasion in triple-negative breast cancer cells

  2022cites this paper
• Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC

  2022cites this paper
• Anti-CD44 and EGFR Dual-Targeted Solid Lipid Nanoparticles for Delivery of Doxorubicin to Triple-Negative Breast Cancer Cell Line: Preparation, Statistical Optimization, and In Vitro Characterization

  2022cites this paper
• USP22 Contributes to Chemoresistance, Stemness, and EMT Phenotype of Triple-Negative Breast Cancer Cells by egulating the Warburg Effect via c-Myc Deubiquitination.

  2022cites this paper
• Targeting hypoxia-inducible factor-1alpha: A new strategy for triple-negative breast cancer therapy.

  2022cites this paper
• RON Receptor Tyrosine Kinase in Tumorigenic Stemness as a Therapeutic Target of Antibody-Drug Conjugates for Eradication of Triple-Negative Breast Cancer Stem Cells.

  2022cites this paper
• LLL12B, a Novel Small-Molecule STAT3 Inhibitor, Induces Apoptosis and Suppresses Cell Migration and Tumor Growth in Triple-Negative Breast Cancer Cells

  2022cites this paper
• Cancer stem cells in esophageal squamous cell carcinoma.

  2022cites this paper
• Addiction of Cancer Stem Cells to MUC1-C in Triple-Negative Breast Cancer Progression

  2022cites this paper
• Insights into Intra-Tumoral Heterogeneity: Transcriptional Profiling of Chemoresistant MPM Cell Subpopulations Reveals Involvement of NFkB and DNA Repair Pathways and Contributes a Prognostic Signature

  2021cites this paper
• A novel three-long noncoding RNA risk score system for the prognostic prediction of triple-negative breast cancer.

  2021cites this paper
• Aurora-A kinase oncogenic signaling mediates TGF-β-induced triple-negative breast cancer plasticity and chemoresistance

  2021cites this paper
• The Role of Autophagy and lncRNAs in the Maintenance of Cancer Stem Cells

  2021cites this paper
• An insight into the cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer.

  2021cites this paper
• Zinc Complex of 3,5-di-tert-butyl Salicylate Inhibits the Proliferation, Migration, and Invasion of Triple-Negative Breast Cancer Cells

  2021cites this paper
• Molecular Pathways and Epigenetic Factors Regulating Chemoresistance in Cancer

  2021cites this paper
• The Role of Breast Cancer Stem Cells in Chemoresistance and Metastasis in Triple-Negative Breast Cancer

  2021cites this paper
• Curcumin and Glu-GNPs Induce Radiosensitivity against Breast Cancer Stem-Like Cells

  2020cites this paper
• Construction of a Novel 3-lncRNA Risk Score System for the Prognostic Prediction of Triple-Negative Breast Cancer

  2020cites this paper
• Bioengineered siRNA-Based Nanoplatforms Targeting Molecular Signaling Pathways for the Treatment of Triple Negative Breast Cancer: Preclinical and Clinical Advancements

  2020cites this paper
• Effects of Cancer Stem Cells in Triple-Negative Breast Cancer and Brain Metastasis: Challenges and Solutions

  2020cites this paper
• RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC

  2020cites this paper
• A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction.

  2020cites this paper
• MAOA-mediated reprogramming of stromal fibroblasts promotes prostate tumorigenesis and cancer stemness

  2020cites this paper
• Doxorubicin and α-Mangostin oppositely affect luminal breast cancer cell stemness evaluated by a new retinaldehyde-dependent ALDH assay in MCF-7 tumor spheroids.

  2020cites this paper
• C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition.

  2019cites this paper
• STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review

  2019cites this paper
• CD155 contributes to the mesenchymal phenotype of triple‐negative breast cancer

  2019cites this paper
• Cancer stem cells in esophageal squamous cell cancer

  2019cites this paper
• Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness

  2019cites this paper
• Phenotypic, structural, and ultrastructural analysis of triple-negative breast cancer cell lines and breast cancer stem cell subpopulation

  2019cites this paper
• Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer—How We Can Rise to the Challenge

  2019cites this paper
• Amentoflavone inhibits tumorsphere formation by regulating the Hedgehog/Gli1 signaling pathway in SUM159 breast cancer stem cells

  2019cites this paper
• Piperlongumine Induces Apoptosis and Synergizes with Doxorubicin by Inhibiting the JAK2-STAT3 Pathway in Triple-Negative Breast Cancer

  2019cites this paper
• Targeting cancer stem cells and their niche: perspectives for future therapeutic targets and strategies.

  2018cites this paper
• Ganoderma lucidum extract (GLE) impairs breast cancer stem cells by targeting the STAT3 pathway

  2018cites this paper
• Cancer stem cell markers ALDH1 and CD44+/CD24– phenotype and their prognosis impact in invasive ductal carcinoma

  2018cites this paper
• Breast cancer stem cells: Features, key drivers and treatment options.

  2018cites this paper